MedTrace Logo

The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients

NCT00629252 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-09-17

No results posted yet for this study

Summary

This study aims to investigate whether the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole modulates or improves both subcortical and cortical information processing in schizophrenic patients who had not or insufficiently responded to previous antipsychotic medication. This goal shall be accomplished by investigating the effect of sertindole of both prepulse inhibition of the acoustic startle (PPI) and P50 suppression of auditory evoked potentials in schizophrenic patients. These effects shall be compared to the effect of risperidone and shall also be compared to untreated healthy controls.

Conditions

Interventions

DRUG

Sertindole

oral 12-20 mg/day

DRUG

Risperidone

oral 2-6mg / day

Sponsors & Collaborators

  • University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging

    collaborator OTHER

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Franz X. Vollenweider, Prof. Dr. med. · University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00629252 on ClinicalTrials.gov